All Articles
Real-world data indicate the efficacy and safety profile of the biosimilar trastuzumab-dttb + pertuzumab was consistent with that previously reported for trastuzumab reference + pertuzumab in patients with HER2-positive breast cancer. Read More ›
The quality metrics that were put in place with the Oncology Care Model (OCM) support the lowering of costs. When navigators use AONN+'s Metrics Toolkit, their metrics can coincide with those that are being used in OCM. Read More ›
Patient-reported outcomes from the phase 3 PRIMA clinical trial showed no detrimental effect of niraparib on quality-of-life measures compared with placebo in patients with newly diagnosed ovarian cancer. Read More ›
Information on clinical aspects of COVID-19 and social and financial support services for the cancer community are abundant. Read More ›
In a systematic literature review that extracted data from 50 qualifying clinical trials, PARP inhibitor first-line maintenance improved progression-free survival (PFS) “across the board” versus other maintenance treatments in women with advanced ovarian cancer. Read More ›
In a single-arm, single-institution study, combining pembrolizumab, bevacizumab, and metronomic oral cyclophosphamide led to a median progression-free survival of 10 months in women with recurrent ovarian cancer, with better response in women with platinum-sensitive disease. Read More ›
An online educational tool about PARP inhibitors improved clinicians’ confidence in their ability to use them correctly in women with newly diagnosed advanced ovarian cancer. Read More ›
Rani Khetarpal shares the 3 payment avenues for the Oncology Care Model. Read More ›
Within the Oncology Care Model, the largest costs are attributed to drugs and in-patient hospitalizations. Oncology nurse and patient navigators are essential to reducing emergency room utilization and hospitalizations. Read More ›
The Oncology Care Model has made a positive impact on improving access and appropriateness to care while keeping the care patient-centered. Read More ›